Microdosing refers to the practice of using psychedelics repeatedly below the threshold for perceptual alterations.

A recent series of case studies provided promising preliminary evidence for the potential of microdosing in treating chronic pain.

At the federal level, psilocybin in listed as a Schedule I drug. The use, sale, and possession of psilocybin in

Currently, there is no empirical evidence available that supports the absorption of psychedelic compounds such as psilocybin through skin pores.

To date, there is currently limited-to-no available evidence-based knowledge on dosage method comparisons for microdosing.

Psychedelic integration is a critical component of understanding and incorporating the knowledge and lessons gained during the psychedelic experience.